← Leaderboards
Timothy R Fouts
University Of Md Biotechnology Institute
$18,775,658
Attributed
$23,622,779
Total exposure
11
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.6M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$23,622,779 · 11
By mechanism
R01$11,422,981 · 3
R44$8,369,651 · 4
N01$3,535,504 · 2
R43$294,643 · 1
P01$0 · 1
Top collaborators
- Antony Dimitrov9 shared
Most similar at University Of Md Biotechnology Institute
Same institution · by research overlap
- John P Marino$1,941,633
Others in their field
Top investigators on “Dose”
- Lawrence Corey · Fred Hutchinson Cancer Center$251,944,397
- Sharon A Nachman · Johns Hopkins University$213,337,729
- David Heimbrook · Leidos Biomedical Research, Inc.$146,807,554
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$134,297,561
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$124,321,134
- Peter C Adamson · National Childhood Cancer Foundation$122,197,823
Research focus
DoseAnimalsAntigensBaseClinical TrialsVaccinesAdjuvantEvaluationImmunogenicityProductionToxicologyPre-ClinicalProphylacticVirusVaccinationImmune ResponseResponseResearch Clinical TestingHiv VaccineAntibodiesProteinsSeedsCharacteristicsHiv-1
Grant awards (31)
NIAID Preclinical Development Support: Essential Core Activities$333,464
N01 · FY2025 · AI · contact PI
Feasibility for Development of a Liposome/LNP Displaying an HIV Env Trimer Protein and Containing/Incorporating an mRNA$1,863,405
N01 · FY2024 · AI · contact PI
NIAID Preclinical Development Support: Essential Core Activities$712,914
N01 · FY2024 · AI · contact PI
Long Term Stability Testing of a Nanoparticle Based HIV Envelope Containing Vaccine$625,721
N01 · FY2024 · AI · contact PI
Development of sG as a human vaccine against Nipah/Hendra$1,129,038
R01 · FY2016 · AI · contact PI
Development of sG as a human vaccine against Nipah/Hendra$1,035,051
R01 · FY2015 · AI · contact PI
An HIV Vaccine Strategy Based on Priming with rVSV Expressing FLSC$1,000,000
R44 · FY2015 · AI · contact PI
Preclinical Development of m102.4, a Human Anti-Hendra and Nipah Antibody$984,776
R01 · FY2015 · AI · contact PI
Preclinical Development of m102.4, a Human Anti-Hendra and Nipah Antibody$1,182,666
R01 · FY2014 · AI · contact PI
Optimization of a DNA Subunit Regimen for an HIV Vaccine$999,999
R44 · FY2014 · AI · contact PI
Development of sG as a human vaccine against Nipah/Hendra$970,588
R01 · FY2014 · AI · contact PI
Optimization of a DNA Subunit Regimen for an HIV Vaccine$450,792
R44 · FY2014 · AI · contact PI
An HIV Vaccine Strategy Based on Priming with rVSV Expressing FLSC$300,000
R44 · FY2014 · AI · contact PI
Preclinical Development of m102.4, a Human Anti-Hendra and Nipah Antibody$1,039,531
R01 · FY2013 · AI · contact PI
Development of sG as a human vaccine against Nipah/Hendra$990,669
R01 · FY2013 · AI · contact PI
Optimization of a DNA Subunit Regimen for an HIV Vaccine$700,194
R44 · FY2013 · AI · contact PI
Development of sG as a human vaccine against Nipah/Hendra$1,306,446
R01 · FY2012 · AI · contact PI
Preclinical Development of m102.4, a Human Anti-Hendra and Nipah Antibody$1,097,778
R01 · FY2012 · AI · contact PI
Preclinical Development of Full Length Single Chain$973,622
R44 · FY2012 · AI · contact PI
Enhancing DNA vaccines using modified Bacterial Toxin A1 Subunits as adjuvants$952,926
R44 · FY2012 · AI · contact PI
Optimization of a DNA Subunit Regimen for an HIV Vaccine$224,027
R44 · FY2012 · AI · contact PI
Preclinical Development of m102.4, a Human Anti-Hendra and Nipah Antibody$1,086,738
R01 · FY2011 · AI · contact PI
Preclinical Development of Full Length Single Chain$997,069
R44 · FY2011 · AI · contact PI
Enhancing DNA vaccines using modified Bacterial Toxin A1 Subunits as adjuvants$961,830
R44 · FY2011 · AI · contact PI
Enhancing DNA vaccines using modified Bacterial Toxin A1 Subunits as adjuvants$509,934
R44 · FY2010 · AI · contact PI
Preclinical Development of Full Length Single Chain$299,258
R44 · FY2010 · AI · contact PI
Enhancing DNA vaccines using modified Cholera Toxin A1 Subunit as an adjuvant$294,643
R43 · FY2007 · AI · contact PI
Assessment of mFLSC(239)complex in cynomologus macaques$267,968
R01 · FY2006 · AI · contact PI
Assessment of mFLSC(239)complex in cynomologus macaques$331,732
R01 · FY2005 · AI
BA/GP120/CD4 IMMUNOADHESION AS VAGINAL MICROBICIDE$0
P01 · FY2002 · AI
BA/GP120/CD4 IMMUNOADHESION AS VAGINAL MICROBICIDE$0
P01 · FY2001 · AI